drugset / Trial / NCT00658359
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients through Month 36 posttransplant. Patients will continue their study medications that were previously assigned.
Timeline
- Start
- 2008-08
- Primary completion
- 2015-03
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | — | — |
| Subject | Tofacitinib | Small molecule | — | — |
Indications
No indication recorded.